Oxford Biomedica

This morning, we released our 2024 full year trading update, showcasing our strong financial, operational, and commercial performance. The results we shared demonstrate the continued progress we’re making as a pure-play CDMO and the successful execution of our multi-vector, multi-site "One OXB" strategy.   Highlights include:   🔹 Growing demand for our CDMO services, with new lenti and AAV orders, as well as other viral vectors 🔹 Orders for additional batches for late-stage programmes for clients preparing for commercialisation of their products 🔹 >78% organic revenue growth in the full year and order book almost doubling since August 🔹 Successful enablement of lentiviral vector manufacturing at our sites in France   Read the full announcement: https://lnkd.in/eDbwYYXd    #CDMO #CellAndGeneTherapy #ViralVectors #OXB

Today, we're excited to showcase the work of our Senior Scientist, Ben Alberts, whose latest poster highlights key advancements in lentiviral vector (LV) production and engineering. At OXB, our 4th generation LV delivery system (the 𝗧𝗲𝘁𝗿𝗮𝗩𝗲𝗰𝘁𝗮™ 𝘀𝘆𝘀𝘁𝗲𝗺) is transforming LV manufacturing with four key innovations designed to enhance quality, safety, efficiency, and scalability: 🔹 𝟮𝗞𝗢 𝗚𝗲𝗻𝗼𝗺𝗲™ - Eliminates spliced vector RNA subspecies during production, ensuring exclusively full-length vector genomes for improved safety and quality.  🔹 𝗦𝘂𝗽𝗔-𝗟𝗧𝗥™ - Enhances transgene expression while minimising unwanted transcriptional interactions, optimising LV performance.  🔹 𝗧𝗥𝗶𝗣 𝗦𝘆𝘀𝘁𝗲𝗺™ - Suppresses transgene expression during production to prevent negative impacts on titres and product purity.  🔹 𝗠𝗮𝘅𝗣𝗮𝘅™ - Expands capacity for large transgenes, simplifying production with a streamlined 3-plasmid system. Take a closer look at Ben Alberts' poster here:   https://lnkd.in/exWXWxuJ #AdvancedTherapies #CellAndGeneTherapy #LentiviralVectors #ViralVectors #TetraVecta #OXBInnovation #TeamOXB #CDMO 

“𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗲𝘃𝗲𝗿𝘆𝗱𝗮𝘆 𝗹𝗶𝗳𝗲 𝗰𝗮𝗻𝗻𝗼𝘁 𝗮𝗻𝗱 𝘀𝗵𝗼𝘂𝗹𝗱 𝗻𝗼𝘁 𝗯𝗲 𝘀𝗲𝗽𝗮𝗿𝗮𝘁𝗲𝗱.” In the early 1950s, Rosalind Franklin’s pioneering work in X-ray crystallography captured the first clear image of DNA’s double helix, a discovery that changed the course of molecular biology. Yet, like many women in science, her contributions weren’t fully recognised in her time.    At OXB, we know that progress in science happens when diverse minds come together. That’s why we’re proud that 𝟰𝟱% 𝗼𝗳 𝗼𝘂𝗿 𝗹𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 𝗿𝗼𝗹𝗲𝘀 𝗮𝗿𝗲 𝗵𝗲𝗹𝗱 𝗯𝘆 𝘄𝗼𝗺𝗲𝗻 today. There’s still work to do, but today on International Day of Women and Girls in Science, we celebrate the women driving biotech forward and those who paved the way.    #InternationalDayofWomenandGirlsinScience #WomenInScience #DiversityInSTEM #TeamOXB #OXB #CDMO 

At OXB, we recently hosted a Neurodiversity Awareness session, organised by our Neurodiversity Employee Network Group, as part of our ongoing commitment to fostering an inclusive workplace. The session, led by Melanie Francis Chartered FCIPD, founder of Neuroinclusive HR, sparked great discussions on the importance of understanding and supporting neurodivergent colleagues. As we continue into 2025, we remain focused on building an environment where everyone can thrive. 𝗪𝗵𝗮𝘁 𝗶𝗻𝗶𝘁𝗶𝗮𝘁𝗶𝘃𝗲𝘀 𝗵𝗮𝘃𝗲 𝗺𝗮𝗱𝗲 𝗮 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗶𝗻 𝘆𝗼𝘂𝗿 𝘄𝗼𝗿𝗸𝗽𝗹𝗮𝗰𝗲? We’d love to hear your thoughts below! 👇 #Neurodiversity #Inclusion #EDI #TeamOXB #CDMO #OXB 

In a recent interview with The Medicine Maker, our CEO, Dr. Frank Mathias, shared what drives him. From his early days watching his father mix formulas in his pharmacy to leading OXB through its transformation into a pure-play CDMO, Frank reflects on the moments that shaped his career, the challenges and rewards of being a CEO, and the future of the advanced therapies field. "𝘉𝘦𝘪𝘯𝘨 𝘱𝘢𝘳𝘵 𝘰𝘧 𝘵𝘩𝘦 𝘤𝘦𝘭𝘭 𝘢𝘯𝘥 𝘨𝘦𝘯𝘦 𝘵𝘩𝘦𝘳𝘢𝘱𝘺 𝘧𝘪𝘦𝘭𝘥 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘤𝘳𝘦𝘥𝘪𝘣𝘭𝘦 𝘱𝘳𝘪𝘷𝘪𝘭𝘦𝘨𝘦. 𝘛𝘩𝘦𝘴𝘦 𝘵𝘩𝘦𝘳𝘢𝘱𝘪𝘦𝘴 𝘩𝘢𝘷𝘦 𝘵𝘩𝘦 𝘱𝘰𝘵𝘦𝘯𝘵𝘪𝘢𝘭 𝘵𝘰 𝘤𝘶𝘳𝘦 𝘭𝘪𝘧𝘦-𝘵𝘩𝘳𝘦𝘢𝘵𝘦𝘯𝘪𝘯𝘨 𝘥𝘪𝘴𝘦𝘢𝘴𝘦𝘴, 𝘰𝘧𝘧𝘦𝘳𝘪𝘯𝘨 𝘯𝘦𝘸 𝘩𝘰𝘱𝘦 𝘵𝘰 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘩𝘰 𝘱𝘳𝘦𝘷𝘪𝘰𝘶𝘴𝘭𝘺 𝘩𝘢𝘥 𝘯𝘰𝘯𝘦." One of the biggest shifts he sees? The industry’s growing reliance on CDMOs to accelerate innovation and make these life-changing therapies more accessible to patients worldwide. Read the full interview here: https://lnkd.in/e4kWSwXh   #AdvancedTherapies #CellAndGeneTherapy #Leadership #InThoughtWithOXB #CDMO #OXB

We’re delighted to be named finalists in three categories at the Thames Valley Business Awards!   🔹 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗼𝗿 𝗼𝗳 𝘁𝗵𝗲 𝗬𝗲𝗮𝗿 🔹 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗬𝗲𝗮𝗿 🔹 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗟𝗲𝗮𝗱𝗲𝗿 𝗼𝗳 𝘁𝗵𝗲 𝗬𝗲𝗮𝗿   Being recognised among so many outstanding businesses shaping the region is a great reminder of the impact innovation can have—not just in our industry, but in our local community too.    A huge thank you to our team, whose dedication continues to drive progress in advanced therapies. We’re looking forward to celebrating with all the nominees later this month!    #TVBCAwards #OXBInnovation #CellandGeneTherapy #AdvancedTherapies #OXB #CDMO 

Today marked a huge milestone for cell and gene therapy! 🎉    The NHS announced that they will soon offer Casgevy, a groundbreaking gene therapy, to patients with sickle cell disease. This represents a significant step in making advanced therapies more accessible, bringing hope to those with limited treatment options.    Moments like these make us proud to be part of a sector that’s driving real impact and continually pushing the boundaries of innovation to transform patient lives. Congratulations to everyone involved in making this therapy a reality!    Read more: https://lnkd.in/eHNQF45W   #CellAndGeneTherapy #Innovation #PatientImpact #OXB #CDMO 

We’re proud to share that we’ve been shortlisted for the 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗼𝗳 𝘁𝗵𝗲 𝗬𝗲𝗮𝗿 award at the 𝗣𝗟𝗖 𝗔𝘄𝗮𝗿𝗱𝘀 𝟮𝟬𝟮𝟱!    This nomination reflects the significant strides we’ve made as a pure-play CDMO, and it’s a testament to our talented team’s hard work, commitment, and dedication to driving innovation in the field. At OXB, we remain focused on enabling our clients to deliver life-changing therapies to patients, and it’s an honour to see our progress recognised.    Good luck to all the nominees—we look forward to celebrating the achievements of this year’s finalists at the plc awards 2024 ceremony next month!    #PLCAwards #BreakthroughOfTheYear #OXBInnovation #OXB #CDMO 

What an inspiring week we had at Advanced Therapies 2025 in Dallas! From engaging conversations to meaningful new connections, our team found last week’s event to be a powerful showcase of the progress in the advanced therapies sector.    Sometimes, the cell and gene therapy world feels surprisingly small. That was the case when our team ran into Benjamin McLeod at the event. While reading about our new Dual-Plasmid Transfection System, Benjamin shared an unexpected connection: the research featured was developed by 𝗵𝗶𝘀 𝘃𝗲𝗿𝘆 𝗳𝗶𝗿𝘀𝘁 𝘀𝘂𝗽𝗲𝗿𝘃𝗶𝘀𝗼𝗿 𝗶𝗻 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆—𝗻𝗼𝘄 𝗽𝗮𝗿𝘁 𝗼𝗳 𝗼𝘂𝗿 𝘁𝗮𝗹𝗲𝗻𝘁𝗲𝗱 𝗢𝗫𝗕 𝘁𝗲𝗮𝗺! It’s moments like these that remind us how collaboration and shared connections drive the breakthroughs that transform patient outcomes.    The innovation that sparked this connection with Benjamin was developed to address key challenges in manufacturing, ensuring greater scalability and consistency. You can explore our Dual-Plasmid system here: https://lnkd.in/efpwXduZ   Thank you to everyone we met for the inspiring conversations—we’re excited to continue the dialogue. And a special thanks to Benjamin McLeod for sharing this wonderful story and making our week even more memorable!    #ATW25 #CellAndGeneTherapy #ViralVectors #OXBInnovation #SmallWorldBigImpact #MeetOXB #OXB

As the cell and gene therapy sector gains momentum in 2025, it’s clear this is a transformative time for the industry. Our CEO, Dr. Frank Mathias, shares his insights in Citeline’s Scrip Asks, highlighting the sector’s progress and the opportunities ahead. “𝘛𝘩𝘦 𝘤𝘦𝘭𝘭 𝘢𝘯𝘥 𝘨𝘦𝘯𝘦 𝘵𝘩𝘦𝘳𝘢𝘱𝘺 𝘴𝘦𝘤𝘵𝘰𝘳 𝘤𝘰𝘯𝘵𝘪𝘯𝘶𝘦𝘴 𝘵𝘰 𝘥𝘦𝘮𝘰𝘯𝘴𝘵𝘳𝘢𝘵𝘦 𝘴𝘵𝘳𝘰𝘯𝘨 𝘮𝘰𝘮𝘦𝘯𝘵𝘶𝘮 𝘢𝘴 𝘸𝘦 𝘢𝘱𝘱𝘳𝘰𝘢𝘤𝘩 2025. 𝘐𝘵𝘴 𝘪𝘯𝘤𝘳𝘦𝘢𝘴𝘪𝘯𝘨 𝘮𝘢𝘵𝘶𝘳𝘪𝘵𝘺 𝘪𝘴 𝘦𝘷𝘪𝘥𝘦𝘯𝘤𝘦𝘥 𝘣𝘺 𝘵𝘩𝘦 𝘨𝘳𝘰𝘸𝘪𝘯𝘨 𝘯𝘶𝘮𝘣𝘦𝘳 𝘰𝘧 𝘭𝘢𝘵𝘦-𝘴𝘵𝘢𝘨𝘦 𝘱𝘳𝘰𝘨𝘳𝘢𝘮𝘴 𝘢𝘤𝘳𝘰𝘴𝘴 𝘮𝘶𝘭𝘵𝘪𝘱𝘭𝘦 𝘮𝘰𝘥𝘢𝘭𝘪𝘵𝘪𝘦𝘴. 𝘛𝘩𝘦 𝘱𝘢𝘤𝘦 𝘰𝘧 𝘳𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘺 𝘢𝘱𝘱𝘳𝘰𝘷𝘢𝘭𝘴 𝘪𝘴 𝘱𝘢𝘳𝘵𝘪𝘤𝘶𝘭𝘢𝘳𝘭𝘺 𝘦𝘯𝘤𝘰𝘶𝘳𝘢𝘨𝘪𝘯𝘨, 𝘸𝘪𝘵𝘩 𝘴𝘦𝘷𝘦𝘳𝘢𝘭 𝘤𝘦𝘭𝘭 𝘢𝘯𝘥 𝘨𝘦𝘯𝘦 𝘵𝘩𝘦𝘳𝘢𝘱𝘪𝘦𝘴 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘣𝘺 𝘳𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘴 𝘪𝘯 2024 𝘵𝘰 𝘥𝘢𝘵𝘦 𝘢𝘯𝘥 𝘢𝘥𝘥𝘪𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘱𝘱𝘳𝘰𝘷𝘢𝘭𝘴 𝘢𝘯𝘵𝘪𝘤𝘪𝘱𝘢𝘵𝘦𝘥 𝘪𝘯 𝘵𝘩𝘦 𝘤𝘰𝘮𝘪𝘯𝘨 𝘮𝘰𝘯𝘵𝘩𝘴.” Frank highlighted the evolving role of CDMOs in driving this progress, emphasising the importance of innovation, scalability, and collaboration to bring transformative treatments to patients.  At OXB, we’re proud to play our part in this evolving landscape, by providing our clients with the expertise, flexibility, and solutions they need to succeed in bringing life-changing therapies to market. Read the full article here: https://lnkd.in/enNMqZtU #CellAndGeneTherapy #Innovation #InThoughtWithOXB #CDMO #ViralVectors #OXB